Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection

Luis M. Ruilope, Enrico Agabiti Rosei, George L. Bakris, Giuseppe Mancia, Neil R. Poulter, Stefano Taddei, Thomas Unger, Massimo Volpe, Bernard Waeber, Faiez Zannad

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

In the prevention and treatment of cardiovascular disease, pharmacological treatment strategies should have several aims: (i) in individuals without overt cardiovascular disease, but with risk factors such as hypertension and/or diabetes, pharmacotherapy should prevent or delay disease development; (ii) in patients who have already progressed to cardiovascular disease, pharmacotherapy should help either to prevent or regress target organ damage (TOD); and (iii) in patients with TOD, pharmacotherapy should prevent events. Any medication intended for long-term therapy also should be well tolerated. Inhibiting the renin-angiotensin system has proven a successful therapeutic strategy in cardiovascular and renal medicine. Angiotensin-converting enzyme (ACE) inhibitors have demonstrated important advantages over conventional agents such as beta-blockers and thiazide diuretics, and have become a relevant part of treatment for heart failure post-myocardial infarction, left ventricular dysfunction and renal disease. Tolerability concerns may prevent their use in some patients, however. Angiotensin AT1 receptor blockers (ARBs) provide a different form of blockade of the renin-angiotensin system and a growing body of evidence suggests that this alternative approach may confer additional cardiovascular protection for some patient subgroups. In addition, ARBs generally are better tolerated than ACE inhibitors, enhancing patient compliance and persistence with long-term therapy. Furthermore, evidence in favour of combining an ACE inhibitor and an ARB in certain circumstances is continuously growing.

Original languageEnglish
Pages (from-to)196-209
Number of pages14
JournalBlood Pressure
Volume14
Issue number4
DOIs
Publication statusPublished - 2005

Fingerprint

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Diseases
Renin-Angiotensin System
Drug Therapy
Sodium Chloride Symporter Inhibitors
Kidney
Therapeutics
Angiotensin Type 1 Receptor
Left Ventricular Dysfunction
Patient Compliance
Treatment Failure
Heart Failure
Myocardial Infarction
Medicine
Pharmacology
Hypertension

Keywords

  • Angiotensin AT1 receptor antagonists
  • Cardiovascular diseases
  • Hypertension
  • Renin-angiotensin system

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Ruilope, L. M., Rosei, E. A., Bakris, G. L., Mancia, G., Poulter, N. R., Taddei, S., ... Zannad, F. (2005). Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Pressure, 14(4), 196-209. https://doi.org/10.1080/08037050500230227

Angiotensin receptor blockers : Therapeutic targets and cardiovascular protection. / Ruilope, Luis M.; Rosei, Enrico Agabiti; Bakris, George L.; Mancia, Giuseppe; Poulter, Neil R.; Taddei, Stefano; Unger, Thomas; Volpe, Massimo; Waeber, Bernard; Zannad, Faiez.

In: Blood Pressure, Vol. 14, No. 4, 2005, p. 196-209.

Research output: Contribution to journalArticle

Ruilope, LM, Rosei, EA, Bakris, GL, Mancia, G, Poulter, NR, Taddei, S, Unger, T, Volpe, M, Waeber, B & Zannad, F 2005, 'Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection', Blood Pressure, vol. 14, no. 4, pp. 196-209. https://doi.org/10.1080/08037050500230227
Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S et al. Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Pressure. 2005;14(4):196-209. https://doi.org/10.1080/08037050500230227
Ruilope, Luis M. ; Rosei, Enrico Agabiti ; Bakris, George L. ; Mancia, Giuseppe ; Poulter, Neil R. ; Taddei, Stefano ; Unger, Thomas ; Volpe, Massimo ; Waeber, Bernard ; Zannad, Faiez. / Angiotensin receptor blockers : Therapeutic targets and cardiovascular protection. In: Blood Pressure. 2005 ; Vol. 14, No. 4. pp. 196-209.
@article{c13928742e6e4d97ab85e301bb4a4816,
title = "Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection",
abstract = "In the prevention and treatment of cardiovascular disease, pharmacological treatment strategies should have several aims: (i) in individuals without overt cardiovascular disease, but with risk factors such as hypertension and/or diabetes, pharmacotherapy should prevent or delay disease development; (ii) in patients who have already progressed to cardiovascular disease, pharmacotherapy should help either to prevent or regress target organ damage (TOD); and (iii) in patients with TOD, pharmacotherapy should prevent events. Any medication intended for long-term therapy also should be well tolerated. Inhibiting the renin-angiotensin system has proven a successful therapeutic strategy in cardiovascular and renal medicine. Angiotensin-converting enzyme (ACE) inhibitors have demonstrated important advantages over conventional agents such as beta-blockers and thiazide diuretics, and have become a relevant part of treatment for heart failure post-myocardial infarction, left ventricular dysfunction and renal disease. Tolerability concerns may prevent their use in some patients, however. Angiotensin AT1 receptor blockers (ARBs) provide a different form of blockade of the renin-angiotensin system and a growing body of evidence suggests that this alternative approach may confer additional cardiovascular protection for some patient subgroups. In addition, ARBs generally are better tolerated than ACE inhibitors, enhancing patient compliance and persistence with long-term therapy. Furthermore, evidence in favour of combining an ACE inhibitor and an ARB in certain circumstances is continuously growing.",
keywords = "Angiotensin AT1 receptor antagonists, Cardiovascular diseases, Hypertension, Renin-angiotensin system",
author = "Ruilope, {Luis M.} and Rosei, {Enrico Agabiti} and Bakris, {George L.} and Giuseppe Mancia and Poulter, {Neil R.} and Stefano Taddei and Thomas Unger and Massimo Volpe and Bernard Waeber and Faiez Zannad",
year = "2005",
doi = "10.1080/08037050500230227",
language = "English",
volume = "14",
pages = "196--209",
journal = "Blood Pressure",
issn = "0803-7051",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Angiotensin receptor blockers

T2 - Therapeutic targets and cardiovascular protection

AU - Ruilope, Luis M.

AU - Rosei, Enrico Agabiti

AU - Bakris, George L.

AU - Mancia, Giuseppe

AU - Poulter, Neil R.

AU - Taddei, Stefano

AU - Unger, Thomas

AU - Volpe, Massimo

AU - Waeber, Bernard

AU - Zannad, Faiez

PY - 2005

Y1 - 2005

N2 - In the prevention and treatment of cardiovascular disease, pharmacological treatment strategies should have several aims: (i) in individuals without overt cardiovascular disease, but with risk factors such as hypertension and/or diabetes, pharmacotherapy should prevent or delay disease development; (ii) in patients who have already progressed to cardiovascular disease, pharmacotherapy should help either to prevent or regress target organ damage (TOD); and (iii) in patients with TOD, pharmacotherapy should prevent events. Any medication intended for long-term therapy also should be well tolerated. Inhibiting the renin-angiotensin system has proven a successful therapeutic strategy in cardiovascular and renal medicine. Angiotensin-converting enzyme (ACE) inhibitors have demonstrated important advantages over conventional agents such as beta-blockers and thiazide diuretics, and have become a relevant part of treatment for heart failure post-myocardial infarction, left ventricular dysfunction and renal disease. Tolerability concerns may prevent their use in some patients, however. Angiotensin AT1 receptor blockers (ARBs) provide a different form of blockade of the renin-angiotensin system and a growing body of evidence suggests that this alternative approach may confer additional cardiovascular protection for some patient subgroups. In addition, ARBs generally are better tolerated than ACE inhibitors, enhancing patient compliance and persistence with long-term therapy. Furthermore, evidence in favour of combining an ACE inhibitor and an ARB in certain circumstances is continuously growing.

AB - In the prevention and treatment of cardiovascular disease, pharmacological treatment strategies should have several aims: (i) in individuals without overt cardiovascular disease, but with risk factors such as hypertension and/or diabetes, pharmacotherapy should prevent or delay disease development; (ii) in patients who have already progressed to cardiovascular disease, pharmacotherapy should help either to prevent or regress target organ damage (TOD); and (iii) in patients with TOD, pharmacotherapy should prevent events. Any medication intended for long-term therapy also should be well tolerated. Inhibiting the renin-angiotensin system has proven a successful therapeutic strategy in cardiovascular and renal medicine. Angiotensin-converting enzyme (ACE) inhibitors have demonstrated important advantages over conventional agents such as beta-blockers and thiazide diuretics, and have become a relevant part of treatment for heart failure post-myocardial infarction, left ventricular dysfunction and renal disease. Tolerability concerns may prevent their use in some patients, however. Angiotensin AT1 receptor blockers (ARBs) provide a different form of blockade of the renin-angiotensin system and a growing body of evidence suggests that this alternative approach may confer additional cardiovascular protection for some patient subgroups. In addition, ARBs generally are better tolerated than ACE inhibitors, enhancing patient compliance and persistence with long-term therapy. Furthermore, evidence in favour of combining an ACE inhibitor and an ARB in certain circumstances is continuously growing.

KW - Angiotensin AT1 receptor antagonists

KW - Cardiovascular diseases

KW - Hypertension

KW - Renin-angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=25844476905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844476905&partnerID=8YFLogxK

U2 - 10.1080/08037050500230227

DO - 10.1080/08037050500230227

M3 - Article

C2 - 16126553

AN - SCOPUS:25844476905

VL - 14

SP - 196

EP - 209

JO - Blood Pressure

JF - Blood Pressure

SN - 0803-7051

IS - 4

ER -